Discovery Laboratories announced Tuesday that it has received $1.9 million of a $2.4 million fast-track small business innovation research grant from the National Heart, Lung and Blood Institute of the National Institutes of Health.
The award supports continuing research into the ongoing phase 2a clinical trials for Aerosurf, Discovery Labs’ answer to treating infantile respiratory distress syndrome.
Aerosurf is in development to provide KL4 surfactant therapy through nasal continuous positive airway pressure for afflicted premature infants, according to a Discovery Labs release.
The company said the product has the potential to inspire treatment in a larger number of premature infants who are not currently treated but could benefit from the therapy.
Discovery Labs was notified in 2010 that it was eligible for consideration under the grant program, expecting to fully utilize the $1.9 million this year.
The study is expected to be completed by the end of 2014.